PriceTargets.com logo

Korro Bio - KRRO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $142.17
  • Forecasted Upside: 225.55%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$43.67 As of 12/20/2024 06:16 PM ET
▲ +0.55 (1.28%)

This chart shows the closing price for KRRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Korro Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KRRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KRRO

Analyst Price Target is $142.17
▲ +225.55% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Korro Bio in the last 3 months. The average price target is $142.17, with a high forecast of $180.00 and a low forecast of $105.00. The average price target represents a 225.55% upside from the last price of $43.67.

This chart shows the closing price for KRRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Korro Bio.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
11/13/2024William BlairReiterated RatingOutperform
10/21/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$95.00 ➝ $105.00
10/21/2024Raymond JamesInitiated CoverageStrong-Buy$153.00
10/18/2024HC WainwrightBoost TargetBuy ➝ Buy$100.00 ➝ $115.00
9/19/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$95.00 ➝ $95.00
9/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
8/14/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$105.00 ➝ $95.00
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
8/14/2024William BlairInitiated CoverageOutperform$180.00
5/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00
5/15/2024HC WainwrightLower TargetBuy ➝ Buy$115.00 ➝ $100.00
5/15/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$120.00
3/28/2024HC WainwrightBoost TargetBuy ➝ Buy$100.00 ➝ $115.00
3/27/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$180.00
3/27/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$70.00 ➝ $90.00
3/26/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$120.00
2/27/2024BMO Capital MarketsInitiated CoverageOutperform$120.00
1/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00
12/4/2023HC WainwrightInitiated CoverageBuy$100.00
11/29/2023Royal Bank of CanadaInitiated CoverageOutperform$70.00
11/10/2023Piper SandlerInitiated CoverageOverweight$180.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 14 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Korro Bio logo
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $43.67
Low: $42.86
High: $44.62

50 Day Range

MA: $55.74
Low: $38.61
High: $80.04

52 Week Range

Now: $43.67
Low: $30.00
High: $98.00

Volume

78,785 shs

Average Volume

75,541 shs

Market Capitalization

$409.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Korro Bio?

The following Wall Street research analysts have issued stock ratings on Korro Bio in the last year: BMO Capital Markets, HC Wainwright, Piper Sandler, Raymond James, Royal Bank of Canada, and William Blair.
View the latest analyst ratings for KRRO.

What is the current price target for Korro Bio?

0 Wall Street analysts have set twelve-month price targets for Korro Bio in the last year. Their average twelve-month price target is $142.17, suggesting a possible upside of 225.5%. William Blair has the highest price target set, predicting KRRO will reach $180.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $105.00 for Korro Bio in the next year.
View the latest price targets for KRRO.

What is the current consensus analyst rating for Korro Bio?

Korro Bio currently has 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KRRO will outperform the market and that investors should add to their positions of Korro Bio.
View the latest ratings for KRRO.

What other companies compete with Korro Bio?

Other companies that are similar to Korro Bio include Galapagos, Xencor, Evotec, Arcutis Biotherapeutics and Nurix Therapeutics. Learn More about companies similar to Korro Bio.

How do I contact Korro Bio's investor relations team?

Korro Bio's physical mailing address is 75 HAYDEN AVENUE SUITE 300, LEXINGTON MA, 02421. The company's listed phone number is 781-315-4600 and its investor relations email address is [email protected]. The official website for Korro Bio is www.frequencytx.com. Learn More about contacing Korro Bio investor relations.